Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20189756 | 1.00 | TSHR (0.34) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL24890833 | 0.89 | TSHR (0.32) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL22034874 | 0.77 | TSHR (0.32) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL22034873 | 0.77 | TSHR (0.32) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL22031610 | 0.77 | — | — | |
| SCHEMBL22031609 | 0.77 | — | — | |
| SCHEMBL29800143 | 0.77 | — | — | |
| SCHEMBL22034842 | 0.76 | GRIK1 (0.33) | TSHRGRIK1GRIK2 | |
| SCHEMBL22034841 | 0.76 | GRIK1 (0.33) | TSHRGRIK1GRIK2 | |
| SCHEMBL22079924 | 0.75 | CYP2D6 (0.48) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053258-B2 | Pyrimidine carboxamides as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3544968-B1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200181170-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3544968-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018098413-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
| US-8592452-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20100152236-A1 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053258-B2 | Pyrimidine carboxamides as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | TSHR 3470/4885GRIK1 1487/4885GRIK2 1345/4885 |
| US-20100152236-A1 | Cyclic amine compound | AR, FSHR, NR5A1 | TSHR 66/4885GRIK1 1303/4885GRIK2 2158/4885 |
| US-20200181170-A1 | PYRIMIDINE CARBOXAMIDES AS GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | TSHR 3470/4885GRIK1 1487/4885GRIK2 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.